Trazodone for sleep: what the label actually says

If you were prescribed trazodone for sleep, you were prescribed an antidepressant. That is not a mistake, and it is not a secret — it is one of the most common prescribing patterns in American medicine. But it is worth knowing, because almost everything people assume about a sleep medication is different when the drug was approved for something else.

Here is what the evidence actually says, with every claim linked to the study it came from.

This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own.

Trazodone is not approved for insomnia

Trazodone's FDA approval is for major depressive disorder. Prescribing it for insomnia is off-label — legal, extremely common, and entirely at the prescriber's discretion, but not a use the approval evaluated.

The scale of the gap is the striking part. The 2018 Cochrane review of antidepressants for insomnia notes that trazodone is the most commonly prescribed antidepressant for insomnia in the USA, while stating plainly that the use is off-label [1].

You can see what the approval itself rested on, quoted from the regulatory record rather than paraphrased, on our trazodone approval journey page.

What this does not mean: off-label is not a synonym for baseless or improper. A great deal of good medicine is off-label. It means the evidence for this use has to be judged on its own, rather than borrowed from the approval — which is exactly what the rest of this page does.

What the sleep trials found

The honest summary: a real but modest effect, mostly on how people rate their sleep.

A 2018 meta-analysis of randomised placebo-controlled trials found trazodone improved perceived sleep quality and reduced early awakenings, rather than producing a large gain in overall sleep efficiency [2]. Read that distinction carefully, because it is the practical one — "I feel like I slept better" and "I was asleep for more of the night" are different outcomes, and the trials were kinder to the first.

That resource carries a moderate evidence rating in our library, and the caveat attached to it explains why: the evidence base was seven trials, limited to short-term use.

Study summary: Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials — moderate evidence, 66/100

The part that gets left out: how long the trials ran

Insomnia is frequently treated for months or years. The trials were not that long.

The 2018 Cochrane review found no evidence on long-term use of antidepressants for insomnia, and rated the adverse-event evidence as low certainty [1]. That is a gold-standard review reporting an absence, and an absence of evidence is not the same as evidence of safety — it means the question was not answered.

Study summary: Antidepressants for insomnia in adults — gold standard, 95/100

This is not unique to trazodone. When we audited every study record in the library for how long the trials actually ran, short horizons were the norm rather than the exception — the full trial-duration audit is here.

The side-effect number worth knowing

A 2024 systematic review and meta-analysis found sleep-related adverse effects roughly four times more frequent than with placebo (RR 4.31), and that trial benefits came alongside clearly higher dropout from adverse effects [3].

That review sits at strong evidence in our library, with one caveat recorded honestly: the funding and conflict-of-interest statements were behind the journal's paywall and could not be read, so funding is recorded as unknown rather than assumed clean.

Study summary: Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis — strong evidence, 74/100

If you are taking it for depression, a different study applies

Trazodone at antidepressant doses is a different question from low-dose trazodone for sleep, and the two get conflated constantly.

The largest antidepressant comparison ever conducted — a network meta-analysis of 21 drugs — found several other antidepressants ranked higher than trazodone for treating depression itself [4]. If trazodone is doing double duty in your regimen, that is a reasonable thing to raise.

Study summary: Comparative efficacy and acceptability of 21 antidepressant drugs — gold standard, 100/100

One specific population where the evidence is thinner than you would hope

Trazodone is used for sleep disturbance in dementia. The Cochrane review covering that use found the trazodone evidence came from a single trial of 30 people over two weeks, with negligible effects on night-time awakenings and daytime sleep, and untested longer-term safety in dementia [5].

Study summary: Pharmacotherapies for sleep disturbances in dementia — gold standard, 91/100

Thirty people for two weeks is not a reason to conclude the drug does not work. It is a reason to know how little is actually behind that particular use, especially when the person taking it may not be able to report side effects clearly.

Questions worth taking to your prescriber

These are drawn from the study summaries above — each one exists because a specific finding raises it:

• Was trazodone chosen mainly for depression, or mainly for sleep? (The answer changes which evidence applies.)
• How long am I expected to stay on it — and what is the plan for reviewing that, given the trials were short-term?
• What dose is planned, and how will next-day drowsiness be monitored?
• Which specific sleep problem is this meant to fix — falling asleep, staying asleep, or sleep quality?
• If I want to stop, what taper and check-in plan would you want in place first?
• If a benzodiazepine or z-drug is the alternative being considered, what is the plan for how long that lasts? (the long-term benzodiazepine evidence is here — the trials ran weeks and the use often runs years.)
• Since trazodone is an antidepressant, does stopping it carry the withdrawal and relapse considerations that apply to antidepressants generally?

Why this page shows its working

Every study summary linked above is free to read on the web with no account, and each one carries a trust score calculated from recorded facts about the paper — study design, funding, journal, sample size — rather than typed in by an editor. Where a study has a specific weakness, a written caveat sits next to the score rather than beneath it.

The scoring rubric is public, including the parts that do not flatter us. Browse the whole evidence library if you want to check our work.

If you are in crisis right now, please do not wait: call or text 988 (Suicide & Crisis Lifeline) or text HOME to 741741 (Crisis Text Line). Both are free, confidential and staffed 24/7.